UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Market LLC Indicate by check mark whether the Registrant (1) has filed ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 Common Stock, par value $0.0001 per share ATRA The Nasdaq Stock Market LLC Indicate by check mark whether the Registrant (1) has file ...

INVESTOR PRESENTATION Q4 2022 FEBRUARY 8, 2023 Nasdaq: ATRA Forward-L ...

INVESTOR PRESENTATION Q4 2022 FEBRUARY 8, 2023 Nasdaq: ATRA Forward-L ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdic ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations and Finance Dr. Pascal Touchon - President and Chief Executive Officer Dr. Jakob Dupont - Executive Vice President and Global Head of Research and Development Utpal Koppikar - Chief Financial Officer Dr. AJ Joshi - Chief Medical Officer Conference Call Participants Salim Syed - Mizuho Group John Newman - Canaccord Phil Nadeau - Cowe ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Eric Hyllengren - VP of IR and Finance Pascal Touchon - President and CEO Utpal Koppikar - CFO Jakob Dupont - EVP and Global Head of Research and Development AJ Joshi - Chief Medical Officer Conference Call Participants Salim Syed - Mizuho Tessa Romero - JPMorgan John Newman - Canaccord Ernesto Rodriguez Dumont - Cowen & Co. Michael DiFiore - Evercore ISI Tommie Reerink - Goldman Sachs C ...